Title: CURRENT DIAGNOSIS AND TREATMENT OF ACUTE PANCREATITIS IN
CHINA – A REAL-WORLD, MULTICENTER STUDY
Version: 2 Date: 22 Mar 2021
Reviewer:  Abdullah Yildirim
Reviewer's report:
The authors reviewed the medical records of AP patients from four different hospitals in the
major regions of China and discussed the current status of AP patients and the therapeutic
efficacy of somatostatin analogues. This study demonstrated that the use of somatostatin and
its analogs in AP patients was positively associated with clinical efficacy and that somatostatin
was more effective than octreotide and combined analogs.  I have read it carefully and I think
there are some points that need clarification.
1. There are many definitions that need to be explained in the method part of the study.
2. According to which criteria was the diagnosis and severity of acute pancreatitis? Atlanta
criteria or other criteria?
3. Somatostatin and octreotide doses and administration duration are not clearly defined. The
drug's adverse events were not described.
4. What does the somatostatin / octreotide treatment arm define? Combination therapy, add on
(addition) or switch to another (replacement)?
5. The total number of patients who received and did not receive medication according to
the flowchart is 2099. However, the number of patients included in the study is 2775 (2437
medication arm and 338 no medication arm). There is a mistake in flowchart.
6. Complications were 7.0% in the somatostatin group, 8.6% in the octreotide group and 10.9%
in the somatostatin / octreotide group (line 191-192). What complications?  Complications due
to medication or acute pancreatitis?
7. The authors suggested that it was statistically significant in terms of hospital stay days,
complications, organ failure, and ICU admission (P <0.05). However, there was no significant
difference between no-medication and medication groups in cases of entering the intensive
care unit (13.3% vs 9.3%, p = 0.24). (According to Supplementary Table 1). This is a serious
confusion that needs to be solved.
8. Why there is a difference between somatostatin and octreotide has not been evaluated in the
discussion section.
Title: CURRENT DIAGNOSIS AND TREATMENT OF ACUTE PANCREATITIS IN
CHINA – A REAL-WORLD, MULTICENTER STUDY
Version: 2 Date: 22 Mar 2021
Reviewer:  Abdullah Yildirim
Reviewer's report:
The authors reviewed the medical records of AP patients from four different hospitals in the
major regions of China and discussed the current status of AP patients and the therapeutic
efficacy of somatostatin analogues. This study demonstrated that the use of somatostatin and
its analogs in AP patients was positively associated with clinical efficacy and that somatostatin
was more effective than octreotide and combined analogs.  I have read it carefully and I think
there are some points that need clarification.
1. There are many definitions that need to be explained in the method part of the study.
2. According to which criteria was the diagnosis and severity of acute pancreatitis? Atlanta
criteria or other criteria?
3. Somatostatin and octreotide doses and administration duration are not clearly defined. The
drug's adverse events were not described.
4. What does the somatostatin / octreotide treatment arm define? Combination therapy, add on
(addition) or switch to another (replacement)?
5. The total number of patients who received and did not receive medication according to
the flowchart is 2099. However, the number of patients included in the study is 2775 (2437
medication arm and 338 no medication arm). There is a mistake in flowchart.
6. Complications were 7.0% in the somatostatin group, 8.6% in the octreotide group and 10.9%
in the somatostatin / octreotide group (line 191-192). What complications?  Complications due
to medication or acute pancreatitis?
7. The authors suggested that it was statistically significant in terms of hospital stay days,
complications, organ failure, and ICU admission (P <0.05). However, there was no significant
difference between no-medication and medication groups in cases of entering the intensive
care unit (13.3% vs 9.3%, p = 0.24). (According to Supplementary Table 1). This is a serious
confusion that needs to be solved.
8. Why there is a difference between somatostatin and octreotide has not been evaluated in the
discussion section.
Please review this paper.
user
Title: CURRENT DIAGNOSIS AND TREATMENT OF ACUTE PANCREATITIS IN
CHINA – A REAL-WORLD, MULTICENTER STUDY
Version: 2 Date: 22 Mar 2021
Reviewer:  Abdullah Yildirim
Reviewer's report:
The authors reviewed the medical records of AP patients from four different hospitals in the
major regions of China and discussed the current status of AP patients and the therapeutic
efficacy of somatostatin analogues. This study demonstrated that the use of somatostatin and
its analogs in AP patients was positively associated with clinical efficacy and that somatostatin
was more effective than octreotide and combined analogs.  I have read it carefully and I think
there are some points that need clarification.
1. There are many definitions that need to be explained in the method part of the study.
2. According to which criteria was the diagnosis and severity of acute pancreatitis? Atlanta
criteria or other criteria?
3. Somatostatin and octreotide doses and administration duration are not clearly defined. The
drug's adverse events were not described.
4. What does the somatostatin / octreotide treatment arm define? Combination therapy, add on
(addition) or switch to another (replacement)?
5. The total number of patients who received and did not receive medication according to
the flowchart is 2099. However, the number of patients included in the study is 2775 (2437
medication arm and 338 no medication arm). There is a mistake in flowchart.
6. Complications were 7.0% in the somatostatin group, 8.6% in the octreotide group and 10.9%
in the somatostatin / octreotide group (line 191-192). What complications?  Complications due
to medication or acute pancreatitis?
7. The authors suggested that it was statistically significant in terms of hospital stay days,
complications, organ failure, and ICU admission (P <0.05). However, there was no significant
difference between no-medication and medication groups in cases of entering the intensive
care unit (13.3% vs 9.3%, p = 0.24). (According to Supplementary Table 1). This is a serious
confusion that needs to be solved.
8. Why there is a difference between somatostatin and octreotide has not been evaluated in the
discussion section.
assistant